KRYS — Krystal Biotech Share News
0.000.00%
Last trade - 00:00- $9.77bn
- $8.92bn
- $389.13m
Krystal Biotech Inc reports results for the quarter ended in March - Earnings Summary
Krystal Biotech Inc expected to post a loss of $1.44 a share - Earnings Preview
Brief: Krystal Biotech Announces Clinical Data On Topical Application Of B-VEC
William Blair sees likely FDA approval for 12 gene therapies by year end
Brief: Jeune Aesthetics Doses First Subject In Phase 1 Study Of Kb301 For Improvement Of Lateral Canthal Lines At Rest
Brief: Krystal Biotech Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Krystal Biotech Inc reports results for the quarter ended in December - Earnings Summary
Brief: Krystal Biotech reports Q4 net loss per share of USD 1.25
Krystal Biotech Inc expected to post a loss of $1.32 a share - Earnings Preview
Krystal Biotech up on Europe's 'orphan drug' status for cystic fibrosis therapy
Brief: Krystal Biotech Receives European Commission Orphan Tag For Cystic Fibrosis Treatment
Brief: Krystal Biotech Announces FDA’s 3-Month Extension Of BLA PDUFA Date, Regulatory Update For B-VEC
Brief: Jeune Aesthetics Announces Positive Durability Results For An Investigational Treatment For Improvement Of Fine Lines And Wrinkles
U.S. STOCKS ON THE MOVE-Boeing, U.S. energy, Delek US
Krystal Biotech up on smaller-than-expected Q3 loss
Krystal Biotech Inc reports results for the quarter ended in September - Earnings Summary
Brief: Krystal Biotech Reports Q3 Loss Per Share Of $1.17
Krystal Biotech Inc expected to post a loss of $1.22 a share - Earnings Preview
Brief: FDA Accepts Krystal Biotech's BLA For Dystrophic Epidermolysis Bullosa